Clinical use of Humulin R U-500 insulin in the UK: results of the first Association of British Clinical Diabetologists’ U-500 audit
Abstract
Keywords
References
De la Pena A, Riddle M, Morrow LA, et al. Pharmacokinetic and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care 2011;34:2496–501. http://dx.doi.org/10.2337/dc11-0721
De la Pena A, Ma X, Reddy S, Ovalle F, Bergenstal RM, Jackson JA. Application of PK/PD modelling and simulation to dosing regimen optimisation of high-dose human regular U-500 insulin. J Diabetes Sci Technol 2014;8:821–9. http://dx.doi.org/10.1177/1932296814532326
Jones P, Idris I. The use of U-500 regular insulin in the management of patients with obesity and insulin resistance. Diabetes Obes Metab 2013;15:882–7. http://dx.doi.org/10.1111/dom.12094
Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol 2012;6:412–20. http://dx.doi.org/10.1177/193229681200600229
Eby EL, Wang P, Curtis BH, et al. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. J Med Econ 2013;16:529–38. http://dx.doi.org/10.3111/13696998.2013.772059
Binder C, Brange J. Insulin chemistry and pharmacokinetics. In: Porte D Jr, Sherwin RS (eds). Ellenberg’s and Rifkin’s Diabetes Mellitus. 5th ed. Stamford, CT: Appleton & Lange, 1997, 689.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53. http://dx.doi.org/10.1016/S0140-6736(98)07019-6
Knee TS, Seidensticker DF, Walton JL, Solberg LM, Lasseter DH. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract 2003;9:181–6. http://dx.doi.org/10.4158/EP.9.3.181
Lalej-Bennis D, Selam JL, Fluteau-Nadler S, et al. Extreme insulin resistance: clinical management by external subcutaneous insulin infusion. Diabetes Metab 1997;23:533–6.
Nathan DM, Axelrod L, Flier JS, Carr DB. U-500 insulin in the treatment of antibody-mediated insulin resistance. Ann Intern Med 1981;94:653–6. http://dx.doi.org/10.7326/0003-4819-94-5-653
Boldo A, Comi RJ. Clinical experience with U500 insulin: risks and benefits. Endocr Pract 2012;18:56–61. http://dx.doi.org/10.4158/EP11163.OR
Eby EL, Curtis BH, Gelwicks SC, et al. Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. BMJ Open Diabetes Res Care April 30, 2015 3:e000074. http://dx.doi.org/10.1136/bmjdrc-2014-000074
Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract 2006;12:251–6. http://dx.doi.org/10.4158/EP.12.3.251
Bulchandani DG, Konrady T, Hamburg MS. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract 2007;13:721–5. http://dx.doi.org/10.4158/EP.13.7.721
Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract 2010;16:778–84. http://dx.doi.org/10.4158/EP10014.OR
Lane WS, Weinrib SL, Rappaport JM, Hale CB, Farmer LK, Lane RS. The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin- resistant patients with type 2 diabetes. Endocr Pract 2013;19:196–201. http://dx.doi.org/10.4158/EP12226.OR
Institute for Safe Medication Practices (ISMP). As U-500 insulin safety concerns mount, it’s time to rethink safe use of strengths above U-100. 31 October 2013. In: Acute Care ISMP Medication Safety Alert. Horsham, PA: ISMP. https://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=62
Sanofi. Sanofi receives FDA approval of once-daily basal insulin Toujeo® 2015. http://www.news.sanofi.us/2015-02-25-Sanofi-Receives-FDA-Approval-of-Once-Daily-Basal-Insulin-Toujeo
Cochran E. U-500 insulin: when more with less yields success. Diabetes Spectrum 2009;22:116–22. http://dx.doi.org/10.2337/diaspect.22.2.116
Segal AR, Brunner JE, Burch FT, Jackson JA. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm 2010;67:1526–35. http://dx.doi.org/10.2146/ajhp090554
Medicines and Healthcare Products Regulatory Agency. High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error. Drug Safety Update 2015:3.
Grant P, Chowdhury TA. Drug therapies in diabetes: delivering individualised treatment. Clin Med 2016 (in press).
DOI: https://doi.org/10.15277/bjd.2016.098
Refbacks
- There are currently no refbacks.